Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175816228> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W3175816228 endingPage "7" @default.
- W3175816228 startingPage "793" @default.
- W3175816228 abstract "Peripheral blood lymphocytes from 42 patients and peritoneal cavity lymphocytes from eight patients with advanced ovarian carcinoma were tested for lymphokine-activated killer lymphocyte cytotoxicity against several ovarian carcinoma lines before and after exposure to recombinant interleukin-2 in vitro for 3-5 days. Only four of 42 (9.5%) of peripheral blood lymphocytes and zero of eight (0%) of peritoneal cavity lymphocytes had spontaneous cytotoxicity (greater than 20%) against the ovarian carcinoma lines. After in vitro exposure to recombinant interleukin-2, 41 of 42 (98%) of patients' blood lymphocytes showed a two- to fivefold increase in cytotoxicity against K562 (a lymphoblastoid human target), and 40 of 42 (95%) demonstrated lymphokine-activated killer cytotoxicity (greater than 20%) to the ovarian carcinoma lines. Lymphokine-activated killer activity against fresh allogeneic cell lines was variable, although most patients' peripheral blood lymphocytes (70%) had significant cytotoxicity. By contrast, incubation of patients' peritoneal cavity lymphocytes with recombinant interleukin-2 in vitro did not result in the generation of lymphokine-activated killer cell activity against K562 or ovarian cell lines. Peritoneal lymphocytes did produce lymphokine-activated killer cells in the presence of OK432 in half of the patients tested. The presence of autologous serum during recombinant interleukin-2 activation with blood lymphocytes had an augmentative effect on the resulting lymphokine-activated killer cytotoxicity in two of 20 patients, a suppressive effect in four of 20, and no effect in the other 14 of 20 patients tested.(ABSTRACT TRUNCATED AT 250 WORDS)" @default.
- W3175816228 created "2021-07-05" @default.
- W3175816228 creator A5068863707 @default.
- W3175816228 creator A5078645267 @default.
- W3175816228 creator A5082268368 @default.
- W3175816228 date "1989-05-01" @default.
- W3175816228 modified "2023-09-23" @default.
- W3175816228 title "Lymphocyte activation by recombinant interleukin-2 in ovarian cancer patients." @default.
- W3175816228 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2784847" @default.
- W3175816228 hasPublicationYear "1989" @default.
- W3175816228 type Work @default.
- W3175816228 sameAs 3175816228 @default.
- W3175816228 citedByCount "7" @default.
- W3175816228 crossrefType "journal-article" @default.
- W3175816228 hasAuthorship W3175816228A5068863707 @default.
- W3175816228 hasAuthorship W3175816228A5078645267 @default.
- W3175816228 hasAuthorship W3175816228A5082268368 @default.
- W3175816228 hasConcept C105702510 @default.
- W3175816228 hasConcept C109316439 @default.
- W3175816228 hasConcept C121608353 @default.
- W3175816228 hasConcept C126322002 @default.
- W3175816228 hasConcept C129374314 @default.
- W3175816228 hasConcept C202751555 @default.
- W3175816228 hasConcept C203014093 @default.
- W3175816228 hasConcept C2776090121 @default.
- W3175816228 hasConcept C2777371288 @default.
- W3175816228 hasConcept C2777761686 @default.
- W3175816228 hasConcept C2778102761 @default.
- W3175816228 hasConcept C2778536324 @default.
- W3175816228 hasConcept C2778690821 @default.
- W3175816228 hasConcept C2780427987 @default.
- W3175816228 hasConcept C28651165 @default.
- W3175816228 hasConcept C3019054536 @default.
- W3175816228 hasConcept C49382859 @default.
- W3175816228 hasConcept C55493867 @default.
- W3175816228 hasConcept C71924100 @default.
- W3175816228 hasConcept C86803240 @default.
- W3175816228 hasConcept C8891405 @default.
- W3175816228 hasConceptScore W3175816228C105702510 @default.
- W3175816228 hasConceptScore W3175816228C109316439 @default.
- W3175816228 hasConceptScore W3175816228C121608353 @default.
- W3175816228 hasConceptScore W3175816228C126322002 @default.
- W3175816228 hasConceptScore W3175816228C129374314 @default.
- W3175816228 hasConceptScore W3175816228C202751555 @default.
- W3175816228 hasConceptScore W3175816228C203014093 @default.
- W3175816228 hasConceptScore W3175816228C2776090121 @default.
- W3175816228 hasConceptScore W3175816228C2777371288 @default.
- W3175816228 hasConceptScore W3175816228C2777761686 @default.
- W3175816228 hasConceptScore W3175816228C2778102761 @default.
- W3175816228 hasConceptScore W3175816228C2778536324 @default.
- W3175816228 hasConceptScore W3175816228C2778690821 @default.
- W3175816228 hasConceptScore W3175816228C2780427987 @default.
- W3175816228 hasConceptScore W3175816228C28651165 @default.
- W3175816228 hasConceptScore W3175816228C3019054536 @default.
- W3175816228 hasConceptScore W3175816228C49382859 @default.
- W3175816228 hasConceptScore W3175816228C55493867 @default.
- W3175816228 hasConceptScore W3175816228C71924100 @default.
- W3175816228 hasConceptScore W3175816228C86803240 @default.
- W3175816228 hasConceptScore W3175816228C8891405 @default.
- W3175816228 hasIssue "5 Pt 1" @default.
- W3175816228 hasLocation W31758162281 @default.
- W3175816228 hasOpenAccess W3175816228 @default.
- W3175816228 hasPrimaryLocation W31758162281 @default.
- W3175816228 hasRelatedWork W1535065630 @default.
- W3175816228 hasRelatedWork W1965995080 @default.
- W3175816228 hasRelatedWork W1976280619 @default.
- W3175816228 hasRelatedWork W2062686708 @default.
- W3175816228 hasRelatedWork W2067944906 @default.
- W3175816228 hasRelatedWork W2089170146 @default.
- W3175816228 hasRelatedWork W2415383513 @default.
- W3175816228 hasRelatedWork W2418211735 @default.
- W3175816228 hasRelatedWork W3175816228 @default.
- W3175816228 hasRelatedWork W18987839 @default.
- W3175816228 hasVolume "73" @default.
- W3175816228 isParatext "false" @default.
- W3175816228 isRetracted "false" @default.
- W3175816228 magId "3175816228" @default.
- W3175816228 workType "article" @default.